EGFR/PI3K/Akt signaling pathway with tumor

doi:10.3969/j.issn.1673-8640.2014.07.018

Abstract

Abstract:

Epidermal growth factor receptor（EGFR）/phosphatidylinositol-3-kinase（PI3K）/protein kinase B（PKB，or Akt） signaling pathway is a very important survival signaling pathway. EGFR dimerization pattern can stimulate Ras protein， which leads to a cascade of phosphorylation and activation of PI3K/Akt signaling pathway， and then leads to the occurence of tumors.This review summarizes the relationship between EGFR/PI3K/Akt signaling pathway and tumor by analyzing the function of EGFR/PI3K/Akt signaling pathway.

Key words: Epidermal growth factor receptor, Phosphatidylinositol-3-kinase, Protein kinase B, Tumor

CLC Number:

R446.1

SUN Dongxun,CAI Zhiyi.. EGFR/PI3K/Akt signaling pathway with tumor[J]. , 2014, 29(7): 768-773.

References

[1] Cohen S.Isolation of a mouse submaxillary gland protein accelerating incisor eruption and eyelid opening in the new-born animal[J].J Biol Chem,1962,237: 1555-1562.
[2] Cohen S,Carpenter G,King L Jr. Epidermal growth factor-receptor-protein kinase interactions.Co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity[J].J Biol Chem,1980,255(10):4834-4842.
[3] Naik DS,Sharma S,Ray A,et al.Epidermal growth factor receptor expression in urinary bladder cancer[J].Indian J Urol,2011,27(2):208-214.
[4] Lee ES,Lee Y,Suh D,et al.Detection of HER-2 and EGFR gene amplification using chromogenic in-situ hybridization technique in ovarian tumors[J].Appl Immunohistochem Mol Morphol,2010,18(1):69-74.
[5] Bourouba M,Benyelles-Boufennara A,Terki N,et al. Epidermal growth factor receptor(EGFR) abundance correlates with p53 and Bcl-2 accumulation and patient age in a small cohort of North African nasopharyngeal carcinoma patients[J].Eur Cytokine Netw,2011,22(1):38-44.
[6] Hwangbo W,Lee JH,Ahn S,et al. EGFR gene amplification and protein expression in invasive ductal carcinoma of the breast[J].Korean J Pathol,2013,47(2):107-115.
[7] Kalman B,Szep E,Garzuly F,et al.Epidermal growth factor receptor as a therapeutic target in glioblastoma[J].Neuromolecular Med,2013,15(2):420-434.
[8] Oliveira-Cunha M,Hadfield KD,Siriwardena AK,et al. EGFR and KRAS mutational analysis and their correlation to survival in pancreatic and periampullary cancer[J]. Pancreas,2012,41(3):428-434.
[9] Peraldo-Neia C,Migliardi G,Mello-Grand M,et al.Epidermal growth factor receptor(EGFR) mutation analysis,gene expression profiling and EGFR protein expression in primary prostate cancer[J].BMC Cancer,2011,11:31.
[10] Liu QW,Fu JH,Luo KJ,et al.Identification of EGFR and KRAS mutations in Chinese patients with esophageal squamous cell carcinoma[J].Dis Esophagus,2011.[Epub ahead of print]
[11] Colakoglu T, Yildirim S, Kayaselcuk E, et al. Clinicopathological significance of PTEN loss and the phosphoinositide 3-kinase/Akt pathway in sporadic colorectal neoplasms:is PTEN loss predictor of local recurrence[J].Am J Surg,2008,195(6):719-725.
[12] Cheng GZ,Park S,Shu S,et al.Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery[J].Curr Cancer Drug Targets,2008,8(1):2-6.
[13] Rodrigues GA,Falasca M,Zhang Z,et al.A novel positive feedback loop mediated by the docking protein Gab1 and phosphatidylinositol 3-kinase in epidermal growth factor receptor signaling[J].Mol Cell Biol,2000,20(4):1448-1459.
[14] Sharrard RM,Maitland N. Regulation of protein kinase B activity by PTEN and SHIP2 in human prostate-derived cell lines[J].Cell Signal,2007,19(1):129-138.
[15] Wang JY,Lin CH,Yang CH,et al.Biochemical and biological characterization of a neuroendocrine-associated phosphatase[J].J Neurochem,2006,98(1):89-101.
[16] Lee DH,Szczepanski MJ,Lee YJ.Magnolol induces apoptosis via inhibiting the EGFR/PI3K/Akt signaling pathway in human prostate cancer cells[J].J Cell Biochem,2009,106(6):1113-1122.
[17] Yip WK,Leong VC,Abdullah MA,et al. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor,FKHR and BAD in nasopharyngeal carcinoma[J]. Oncol Rep,2008,19(2):319-328.
[18] Zhang X,Huang X,Olumi AF.Repression of NF-kappaB and activation of AP-1 enhance apoptosis in prostate cancer cells[J].Int J Cancer,2009,124(8):1980-1989.
[19] Xu P,Zhang A,Jiang R,et al. The different role of Notch1 and Notch2 in astrocytic gliomas[J].PLoS One,2013,8(1):e53654.
[20] Hu C,Huang L,Gest C,et al. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression,cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells[J].J Hematol Oncol,2012,5:16.
[21] Lin F,Lin P,Zhao D,et al.Sox2 targets cyclinE,p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis[J].Cell Prolif,2012,45(3):207-216.
[22] Wang C,Lv X,Jiang C,et al. Transforming growth factor alpha (TGFα) regulates granulosa cell tumor (GCT) cell proliferation and migration through activation of multiple pathways[J].PLoS One,2012,7(11): e48299.
[23] Liu ZM,Tseng JT,Hong DY,et al.Suppression of TG-interacting factor sensitizes arsenic trioxide-induced apoptosis in human hepatocellular carcinoma cells[J].Biochem J,2011,438(2):349-358.
[24] Lin JK,Lin-Shiau SY. Mechanisms of hypolipidemic and anti-obesity effects of tea and tea polyphenols[J].Mol Nutr Food Res,2006,50(2):211-217.
[25] Jia J,Zhang W,Liu JY,et al. Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma[J].PLoS One,2012,7(12):e51549.
[26] Guan Z,Wang XR,Zhu XF,et al.Aurora-A,a negative prognostic marker,increases migration and decreases radiosensitivity in cancer cells[J].Cancer Res,2007,67(21): 10436-10444.
[27] Zhang L,Wang F,Jiang Y,et al.Migration of retinal pigment epithelial cells is EGFR/PI3K/AKT dependent[J].Front Biosci(Schol Ed),2013,5:661-671.
[28] Zhao HM,Zhang B,Li Y,et al. Effect of gefitinib on the migration of triple-negative breast cancer cell line MDA-MB-231 cells[J]. Zhonghua Zhong Liu Za Zhi,2012,34(2):84-88.
[29] Dong P,Xu Z,Jia N,et al. Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway[J].Mol Cancer,2009,8:103.
[30] Gao N,Flynn DC,Zhang Z,et al.G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/P70S6KI signaling in human ovarian cancer cells[J].Am J Physiol cell Physiol,2004,287(2):C281-C291.
[31] Lin P,Sun X,Feng T,et al. ADAM17 regulates prostate cancer cell proliferation through mediating cell cycle progression by EGFR/PI3K/AKT pathway[J]. Mol Cell Biochem,2012,359(1-2):235-243.
[32] Chen J,Xia D,Luo JD,et al.Exogenous p27KIP1 expression induces anti-tumour effects inhibits the EGFR/PI3K/Akt signaling pathway in PC3 cells[J].Asian J Androl,2009,11(6): 669-677.
[33] Lin F,Lin P,Zhao D,et al. Sox-2 target cyclinE,p27 and survivin to regulate androgen-independent human prostate cancer cell proliferation and apoptosis[J].Cell Prolif,2012,45(3):207-216.
[34] Gorshtein A,Rubinfeld H,Kendler E,et al.Mammalian target of rapamycin inhibitors rapamycin and RAD001(everolimus) induce anti-proliferative effects in GH-secreting pituitary tumor cells in vitro[J].Endocr Relat Cancer, 2009,16(3):1017-1027.
[35] Yuan Y,Zhang A ,Huang S,et al.A PPARgamma agonist inhibits aldosterone-induced mesangial cell proliferation by blocking ROS-dependent EGFR intracellular signaling[J].Am J Physiol Renal Physiol,2011,300(2):F393-F402.
[36] Manning BD,Cantley LC.AKT/PKB signaling:navigating downstream [J]. Cell,2007,129(7):1261-1274.
[37] Hsieh HL,Lin CC,Chan HJ,et al.c-Src-dependent EGF receptor transactivation contributes to ET-1-induced COX-2 expression in brain microvascular endothelial cells[J].J Neuroinflammation,2012,9:152.
[38] Lin CC,Lee IT,Wu WL,et al. Adenosine triphosphate regulates NADPH oxidase activity leading to hydrogen peroxide production and COX-2/PGE2 expression in A549 cells[J].Am J Physiol Lung Cell Mol Physiol,2012,303(5):L401-L412.
[39] Gordan JD,Simon MC.Hypoxia-inducible factors:central regulators of the tumor phenotype[J].Curr Opin Genet Dev,2007,17(1):71-77.
[40] Lin CC,Lin WN,Cheng SE,et al.Transactivation of EGFR/PI3K/Akt involved in ATP-induced inflammatory protein expression and cell motility[J].J Cell Physiol,2012,227(4):1628-1638.
[41] Fang J,Ding M,Yang L,et al.PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesis[J].Cell Signal,2007,19(12):2487-2497.
[42] Kaidar-Person O,Lai C,Kuten A,et al. "The Infinite Maze" of breast cancer,signaling pathway and radioresistance[J].Breast,2013,22(4):411-418.
[43] Zhou C,Qiu L,Sun Y,et al. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA′s effect on cell death and migration in human ovarian cancer cells[J]. Int J Oncol,2006,29(1):269-278.
[44] Koon HK,Chan PS,Wong RN,et al.Targeted inhibition of the EGFR pathways enhances Zn-BC-AM PDT-induced apoptosis in well-differentiated nasopharyngeal carcinoma cells[J].J Cell Biochem,2009,108(6):1356-1363.
[45] Wang XJ,Feng CW,Li M.ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway[J].Mol Cell Biochem,2013,380(1-2):57-66.
[46] Li P,Torossian A,Zhang Q,et al.Inhibition of phosphoinositide 3-kinase enhances the cytotoxicity of AG1478,an epidermal growth factor receptor inhibitor,in breast cancer cells[J].Med Oncol,2012,29(5):3258-3264.
[47] Porcelli L,Quatrale AE,Mantuano P,et al.Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors[J]. Curr Pharm Des,2013,19(5): 918-926.
[48] Wu HH,Wu JY,Cheng YW,et al. cIAP2 upregulated by E6 oncoprotein via epidermal growth factor receptor/phosphatidylinositol 3-kinase/AKT pathway confers resistance to cisplatin in human papillomavirus 16/18-infected lung cancer[J]. Clin Cancer Res,2010,16(21):5200-5210.
[49] Chen MC,Chen CH,Wang JC,et al.The HDAC inhibitor,MPT0E028,enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells[J].Cell Death Dis,2013,4:e810.
[50] Yu S,Xiao X,Lu J,et al.Colorectal cancer patients with abundance of KRAS mutation may benefit from EGFR antibody therapy[J].PLoS One,2013,8(7):e68022.

[1]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[2]	PENG Wei, LI Yungai, XU Jing, LIU Hua, YANG Cuixia, SHEN Yunyue. Serum inflammatory factors combined with PSA and f-PSA in the auxiliary diagnosis of prostate cancer [J]. Laboratory Medicine, 2023, 38(9): 849-854.
[3]	DING Xiaoyuan, DAI Jinsheng, JIAO Ronghong, MA Suli, ZHU Haifeng, WU Mengya, CHE Yanran, ZHANG Lei. Influence of obesity/overweight on inflammatory factors of Th1/Th2 and Th17/Treg in children with asthma attacks [J]. Laboratory Medicine, 2023, 38(8): 748-752.
[4]	ZHAO Jing, WANG Pei, LU Dandan, QI Dandan, LI Xuan. Expression levels of serum miR-4443 and TRAF4 in patients with hemorrhagic stroke [J]. Laboratory Medicine, 2023, 38(5): 413-418.
[5]	GAO Feng. Clinical application of novel tumor biomarkers：prospects and challenges [J]. Laboratory Medicine, 2023, 38(4): 303-306.
[6]	SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351.
[7]	WU Jiong, HU Jiahua, SHI Meifang, LIU Tao, DAI Jie, LU Xinyi, ZOU Zheng. Research progress of biomarkers of prostate cancer [J]. Laboratory Medicine, 2023, 38(2): 190-195.
[8]	QIAN Linyu, LIANG Weifang, TANG Sichen. Determination and clinical significance of NLRP3，CTRP6 and IL-1β in patients with gestational diabetes mellitus [J]. Laboratory Medicine, 2023, 38(10): 936-940.
[9]	WU Yating, LI Zhuolin, LEI Yan, JIA Ruxue, ZHANG Shenghang, WANG Shuiliang. Research progress of miRNA in urine as a biomarker for common malignant tumors [J]. Laboratory Medicine, 2023, 38(1): 94-99.
[10]	KONG Yujie, WANG Chen, HE Bing. Research progress of N6-methyladenosine in biological function and detection technology [J]. Laboratory Medicine, 2022, 37(9): 872-876.
[11]	WANG Rui, LI Zhaoyan, ZHAO Aiguang. Application of circulating tumor DNA detection in the diagnosis and treatment of gastric cancer [J]. Laboratory Medicine, 2022, 37(9): 877-881.
[12]	LIU Xingqiang, NING Lifen, LI Lin, CHEN Zhongcheng. Correlation of lung cancer clinicopathological characteristics with FR⁺-CTC,ANXA2 and ProGRP [J]. Laboratory Medicine, 2022, 37(8): 735-740.
[13]	WEN Shuzhan, FU Zile, CHEN Shuying. Expression and bioinformatics analysis of hsa-miR-34a in tumors [J]. Laboratory Medicine, 2022, 37(7): 657-663.
[14]	YU Fangfang, ZHAO Qi, YANG Liping, WANG Chenyu. Correlation of hematological indexes and expression of HER-2 in patients with breast cancer [J]. Laboratory Medicine, 2022, 37(6): 514-517.
[15]	GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312.